RVNC Stock Financial Analysis - Revance Therapeutics, Inc. (NasdaqGM) Stock

Overview

Revance Therapeutics, Inc., headquartered in the United States, operates within the biotechnology industry, specializing in the development and commercialization of innovative neuromodulators for aesthetic and therapeutic applications. Its flagship product, DaxibotulinumtoxinA, known as DAXI, represents a significant advancement in the dermal and therapeutic market sectors. This proprietary peptide technology platform has extended the potential uses of botulinum toxin beyond traditional applications. Continuing its expansive trajectory, Revance is involved in diverse projects, encompassing therapeutic treatments for conditions such as cervical dystonia and upper limb spasticity, as well as aesthetic treatments like facial wrinkles. The company strives to disrupt the market by integrating cutting-edge science with substantial patient need, ensuring a robust product pipeline and potential for growth.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted

Cash Flow: Operations, Investing, Financing

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV

Management Effectiveness

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin